These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6802100)

  • 1. Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia.
    van Kammen DP; Docherty JP; Marder SR; Rayner JN; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):275-81. PubMed ID: 6802100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Dalton L; Bunney WE
    Arch Gen Psychiatry; 1982 Mar; 39(3):261-6. PubMed ID: 7065839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.
    van Kammen DP; Docherty JP; Marder SR; Schulz SC; Bunney WE
    Arch Gen Psychiatry; 1980 Mar; 37(3):287-90. PubMed ID: 6102456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
    van Kammen DP; Docherty JP; Bunney WE
    Biol Psychiatry; 1982 Feb; 17(2):233-42. PubMed ID: 7074181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.
    van Kammen DP; Docherty JP; Marder SR; Rosenblatt JE; Bunney WE
    Psychopharmacology (Berl); 1985; 87(1):111-5. PubMed ID: 3933028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimozide treatment of the negative schizophrenic syndrome: an open trial.
    Feinberg SS; Kay SR; Elijovich LR; Fiszbein A; Opler LA
    J Clin Psychiatry; 1988 Jun; 49(6):235-8. PubMed ID: 3288615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.
    Brauer LH; de Wit H
    Biol Psychiatry; 1996 Jan; 39(1):26-32. PubMed ID: 8719123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dextro-amphetamine diminishes negative symptoms in schizophrenia.
    van Kammen DP; Boronow JJ
    Int Clin Psychopharmacol; 1988 Apr; 3(2):111-21. PubMed ID: 3294284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol.
    Silverstone T; Cookson J; Ball R; Chin CN; Jacobs D; Lader S; Gould S
    J Psychiatr Res; 1984; 18(3):255-68. PubMed ID: 6387105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent?
    van Kammen DP; Hommer DW; Malas KL
    Neuropsychobiology; 1987; 18(3):113-7. PubMed ID: 3453426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers.
    Brauer LH; De Wit H
    Pharmacol Biochem Behav; 1997 Feb; 56(2):265-72. PubMed ID: 9050084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pimozide and chlorpromazine in acute schizophrenia.
    Pecknold JC; McClure DJ; Allan T; Wrzesinski L
    Can J Psychiatry; 1982 Apr; 27(3):208-12. PubMed ID: 7046898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.
    van Kammen DP; Bunney WE; Docherty JP; Marder SR; Ebert MH; Rosenblatt JE; Rayner JN
    Am J Psychiatry; 1982 Aug; 139(8):991-7. PubMed ID: 7091448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pimozide in acute schizophrenia: a pilot study.
    Garton D; Silverstone T
    Curr Med Res Opin; 1979; 5(10):799-806. PubMed ID: 373996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pimozide in the treatment of newly admitted schizophrenic patients.
    Chouinard G; Annable L
    Psychopharmacology (Berl); 1982; 76(1):13-9. PubMed ID: 6805002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimozide for schizophrenia or related psychoses.
    Mothi M; Sampson S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.
    Friedman J; Ault K; Powchik P
    Biol Psychiatry; 1997 Sep; 42(6):522-3. PubMed ID: 9285089
    [No Abstract]   [Full Text] [Related]  

  • 18. Comments on the Northwick Park 'Functional' Psychosis Study.
    Goodwin GM; Johnson DA; McCreadie RG
    Br J Psychiatry; 1989 Mar; 154():406-9. PubMed ID: 2688781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prolactin and antipsychotic responses to pimozide in schizophrenia.
    Siris SG; van Kammen DP; De Fraites EG
    Psychopharmacol Bull; 1978 Jan; 14(1):11-4. PubMed ID: 625528
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of pimozide on CSF norepinephrine in schizophrenia.
    Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
    Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.